Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Dec 18, 2015

AltheaDx NeuroIDgenetix Test Expansion

AltheaDx has expanded NeuroIDgenetix, the neuropsychiatric component of its IDgenetix pharmacogenetics (PGx) testing portfolio. The panel now includes PGx testing for medication used to treat both bipolar disorder and seizure disorder. The addition of these two new offerings means the panel now includes a total of six tests for neuropsychiatric disorders (depression, anxiety, bipolar disorder, ADHD, psychosis, and seizure disorder) and four tests for pain (arthritis, migraine, musculoskeletal pain, and neuropathic pain). The expanded panel evaluates a total of 128 FDA-approved neuropsychiatric and pain medications, including mood stabilizers for bipolar disorder and a variety of anticonvulsant medications used to treat seizure disorders. The panel also analyzes 15 clinically validated genes, including those involved in drug metabolism and those that influence individual response to a variety of different medications.


CeGaT New Diagnostic Panels

CeGaT has launched a diagnostic panel for blood and immune disorders, an update and expansion of its diagnostic panel for kidney diseases, and BRCA1/2 testing for ovarian cancer. The new panel for blood and immune disorders contains 14 subpanels that include 297 genes associated with anemia, coagulation disorders, thrombocytopenia, bone marrow failure syndromes, antibody deficiencies, complement deficiencies, autoinflammatory disease, and immune dysregulation. The diagnostic panel for kidney diseases has been updated and expanded to include 182 analyzed genes. In particular, the subpanels for nephronophthisis, renal dysplasia, renal agenesia, CAKUT, nephrotic syndrome, and focal segmental glomerulosclerosis have been expanded to include various differential diagnoses. The new BRCA1/2 diagnostic test determines whether a patient is a good candidate for olaparib therapy, which requires the presence of a mutation in the BRCA1 or BRCA2 genes.


Thermo Scientific 253 HR-IRMS

Thermo Fisher Scientific has launched the 253 Ultra High Resolution Isotope Ratio mass spectrometer (HR-IRMS), which is designed to optimize the measurements of site-specific and clumped-isotope-ratio analysis of molecules. This lets researchers analyze new parameters, including the formation temperatures and degradation processes of molecules, biochemical processes of nitrous oxide, photochemical processes in the atmosphere, and metabolic processes in biochemistry.


For more new products and services, please visit the New Products page on our website. 

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.